![voeding bij traag werkende schildklier voeding bij traag werkende schildklier](https://i.pinimg.com/564x/49/ea/bd/49eabd509d73fa98aa2b00c2c1d0dea4.jpg)
37th Annual Health Care Conference on Tuesday, Maat 8:00 a.m. : ARGX /ISIN: NL0010832176 argenx to Present at Cowen & Co 37th Annual Health Care conference Breda, the Netherlands / Ghent, Belgium- argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its Chief Executive Officer Tim Van Hauwermeiren Chief Executive Officer, will present a company overview at the Cowen & Co. For further information, please contact: Joke Comijn, Corporate Communications and Investor Relations Manager +32 (0)477 77 29 44 +32 (0)9 310 34 19 Beth DelGiacco (US IR) Stern Investor Relations +1 2 07:00 CET 28-02-2017 /GlobeNewswire /Source: argenx N.V. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates. Our ability to execute on this focus is enabled by our suite of differentiated technologies. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. About argenx argenx is a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe autoimmune diseases and cancer. argenx has received licensing fees, research funding, and milestone payments from this collaboration. The initial agreement between Shire and argenx commenced in 2012 and was expanded into a strategic alliance in 2014 granting Shire licenses to the entire suite of argenx discovery technologies. Further details of the extension agreement were not disclosed. argenx shall have the right to in-license any products falling outside Shire's areas of focus on pre-agreed financial terms. argenx will thereafter receive milestone payments as programs proceed through clinical development and royalties on eventual product sales. Upon attainment of specified development criteria, Shire may exercise options - accompanied by a milestone payment to argenx on a per program basis - to take over product development and commercialization. About the strategic alliance with Shire Under the terms of the agreement extension announced today, the parties will continue to progress preclinical development of the most promising programs to have arisen from the collaboration to date. "Extension of this partnership provides both parties the potential to treat the pathophysiology of rare genetic diseases with potentially first-in-class antibody products". "The productivity of our collaboration with Shire has presented exciting product development opportunities in previously untapped target territory", said Debbie Allen, Senior VP Business Development of argenx. : ARGX /ISIN: NL0010832176 argenx announces extension of therapeutic antibody alliance with Shire Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the extension of its strategic partnership with Shire plc (NASDAQ: SHPG) to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.
![voeding bij traag werkende schildklier voeding bij traag werkende schildklier](https://happyhealthy.nl/wp-content/uploads/trage-schildklier.jpg)
Published: 07:00 CET 27-02-2017 /GlobeNewswire /Source: argenx N.V.